Effect Levosimendan Administration on Postoperative NT-proBNP in Cardiac Risk Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

230

Participants

Timeline

Start Date

October 10, 2020

Primary Completion Date

November 7, 2023

Study Completion Date

December 18, 2024

Conditions
Cardiovascular Risk Factor
Interventions
DRUG

Levosimendan

Levosimendan 2.5 mg/ml injection contains levosimendan 2.5 mg, povidone 10.0 mg, citric acid, anhydrous 2.0 mg and ethanol, anhydrous to 1.0 mL. Levosimendan injection is a clear, yellow to orange solution. Immediately after skin incision patients allocated to the verum group will receive a dose of 12.5 mg in 500 mL of levosimendan.

DRUG

Placebo

"Placebo 2.5 mg/ml injection contains riboflavine sodium phosphate 0.4 mg, dehydrated alcohol 100 mg and water for injection to 1 mL.~Immediately after skin incision patients allocated to the placebo group will receive 500 mL of 5% Glucose."

Trial Locations (1)

1100

Medical University of Vienna, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER

NCT04329624 - Effect Levosimendan Administration on Postoperative NT-proBNP in Cardiac Risk Patients | Biotech Hunter | Biotech Hunter